Roche reported positive Phase 3 data for sefaxersen (formerly IONIS-FB-LRx) in primary IgA nephropathy, meeting endpoints in the Imagination study. The self-administered, once-monthly injection produced statistically significant and clinically meaningful improvements in proteinuria versus placebo at 37 weeks, measured by 24-hour urine protein-to-creatinine ratio. Analysts expect the results to support an accelerated FDA filing if Roche pursues U.S. approval. Sefaxersen would become the first mRNA-targeted therapy for IgAN, a kidney disease that saw its treatment landscape expand rapidly since the first IgAN approvals in the early 2020s. Roche has also positioned sefaxersen as part of a broader strategy in kidney disease—an area drawing heavy investment as companies look to differentiate on efficacy and treatment convenience. The Phase 3 readout increases pressure on peers already selling or advancing therapies in the crowded IgAN market.